Ratings Sanofi

Equities

SAN

FR0000120578

Market Closed - Euronext Paris Other stock markets 11:35:34 2024-05-13 am EDT			5-day change	1st Jan Change
92.71 ^EUR	-1.72%		+1.86%	+3.29%

May. 13	Novavax Shares Pop Another 50% Following Sanofi Deal	DJ
May. 13	Top Midday Stories: Return of 'Roaring Kitty' Lifts GameStop Shares; Intel, Apollo Near Deal on Ireland Plant; BHP Latest Offer Rejected by Anglo American; Squarespace Acquired by Permira; Amazon Autonomous Driving Under Probe	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.
The company is in a robust financial situation considering its net cash and margin position.
Analysts covering this company mostly recommend stock overweighting or purchase.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SANOFI	+3.29%	127B	B+
ELI LILLY AND COMPANY	+29.98%	684B	C+
NOVO NORDISK A/S	+30.34%	568B	B
JOHNSON & JOHNSON	-3.52%	361B	C+
MERCK & CO., INC.	+18.59%	329B	B-
ABBVIE INC.	+4.07%	284B	C+
ASTRAZENECA PLC	+16.21%	240B	B+
NOVARTIS AG	+9.66%	208B	B-
ROCHE HOLDING AG	-6.83%	200B	A+
AMGEN INC.	+7.09%	166B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes